Literature DB >> 17726715

Blinded sample size reestimation in non-inferiority trials with binary endpoints.

Tim Friede1, Charles Mitchell, Günther Müller-Velten.   

Abstract

Sample size calculations in the planning of clinical trials depend on good estimates of the model parameters involved. When the estimates of these parameters have a high degree of uncertainty attached to them, it is advantageous to reestimate the sample size after an internal pilot study. For non-inferiority trials with binary outcome we compare the performance of Type I error rate and power between fixed-size designs and designs with sample size reestimation. The latter design shows itself to be effective in correcting sample size and power of the tests when misspecification of nuisance parameters occurs with the former design. (c) 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

Mesh:

Substances:

Year:  2007        PMID: 17726715     DOI: 10.1002/bimj.200610373

Source DB:  PubMed          Journal:  Biom J        ISSN: 0323-3847            Impact factor:   2.207


  6 in total

1.  Spline-based procedures for dose-finding studies with active control.

Authors:  Hans-Joachim Helms; Norbert Benda; Jörg Zinserling; Thomas Kneib; Tim Friede
Journal:  Stat Med       Date:  2014-10-16       Impact factor: 2.373

2.  Cryoballoon vs. open irrigated radiofrequency ablation for paroxysmal atrial fibrillation: long-term FreezeAF outcomes.

Authors:  Armin Luik; Kevin Kunzmann; Patrick Hörmann; Kerstin Schmidt; Andrea Radzewitz; Peter Bramlage; Thomas Schenk; Gerhard Schymik; Matthias Merkel; Meinhard Kieser; Claus Schmitt
Journal:  BMC Cardiovasc Disord       Date:  2017-05-25       Impact factor: 2.298

3.  Drug-coated balloons for de novo lesions in small coronary arteries: rationale and design of BASKET-SMALL 2.

Authors:  Nicole Gilgen; Ahmed Farah; Bruno Scheller; Marc-Alexander Ohlow; Norman Mangner; Daniel Weilenmann; Jochen Wöhrle; Peiman Jamshidi; Gregor Leibundgut; Sven Möbius-Winkler; Robert Zweiker; Florian Krackhardt; Christian Butter; Leonhard Bruch; Christoph Kaiser; Andreas Hoffmann; Peter Rickenbacher; Christian Mueller; Frank-Peter Stephan; Michael Coslovsky; Raban Jeger
Journal:  Clin Cardiol       Date:  2018-05-10       Impact factor: 2.882

4.  Reduction of corticosteroid use in outpatient treatment of exacerbated COPD - Study protocol for a randomized, double-blind, non-inferiority study, (The RECUT-trial).

Authors:  Pascal Urwyler; Maria Boesing; Kristin Abig; Marco Cattaneo; Thomas Dieterle; Andreas Zeller; Herbert Bachler; Stefan Markun; Oliver Senn; Christoph Merlo; Stefan Essig; Elke Ullmer; Jonas Rutishauser; Macé M Schuurmans; Joerg Daniel Leuppi
Journal:  Trials       Date:  2019-12-16       Impact factor: 2.279

5.  Point and Interval Estimators of the Target Dose in Clinical Dose-Finding Studies with Active Control.

Authors:  H-J Helms; N Benda; T Friede
Journal:  J Biopharm Stat       Date:  2014-06-11       Impact factor: 1.051

6.  Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.

Authors:  Kazunari Murakami; Yuuichi Sakurai; Madoka Shiino; Nobuo Funao; Akira Nishimura; Masahiro Asaka
Journal:  Gut       Date:  2016-03-02       Impact factor: 23.059

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.